Randomized trials of amifostine and radiotherapy: effect on survival?
Amifostine (Ethyol; MedImmune Inc, Gaithersburg, MD) is a cytoprotective and radioprotective agent for normal tissues against the deleterious effects of chemotherapeutic agents and/or ionizing radiation. We have compiled a unique database for meta-analysis that aims to address the controversial concept of the tumor protection. The proposed meta-analysis on survival outcome, which is based on individual patient data, will be more useful than literature-based meta-analyses because of the superiority of reliable, longer follow-up patient data. It will be also possible to study the effect(s) of amifostine in different tumor types.
Bourhis
J
J
Department of Radiotherapy, Institut Gustave-Roussy, Villejuif, Cedex France. bourhis@igr.fr
Thephamongkhol
K
K
Pignon
J P
JP
D004999:Amifostine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D019610:Cytoprotection; D019992:Databases as Topic; D006801:Humans; D015201:Meta-Analysis as Topic; D009369:Neoplasms / Q000628:therapy*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
D011837:Radiation-Protective Agents; D004999:Amifostine